{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "RXRX",
  "name": "Recursion Pharmaceuticals, Inc.",
  "url": "https://frontierpicks.com/dossiers/RXRX/",
  "json_url": "https://frontierpicks.com/dossiers/RXRX.json",
  "status": "WATCHLIST",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a3",
    "n": 3
  },
  "current_thesis": "Recursion Pharmaceuticals' early-October short-covering spike has faded, leaving the shares priced on pipeline hope while revenue shrinks; the REC-4881 polyposis data at the 2 November 2026 CGA-IGC plenary decide whether the lead drug can carry the stock.",
  "invalidation_trigger": "A daily close below $3.50, which would give back most of the rally that began in mid-September 2026; REC-4881 data at the 2026-11-02 CGA-IGC plenary that weaken the earlier Phase 2 signal would also break the case.",
  "catalyst_date": "2026-11-02",
  "pick": null,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Recursion has no approved products; revenue comes from partnership and license fees and can swing sharply from quarter to quarter.",
    "The company's cash runway guidance of 'into early 2028' assumes no additional financing; a shorter runway would raise the likelihood of share issuance.",
    "Short interest above 30% of float makes the shares prone to sharp moves in either direction that have no link to company news.",
    "ARK Investment Management's ARKK and ARKG funds are large holders, and their daily trades can move the shares on days without company news."
  ],
  "body_markdown": "## Current Thesis\n\nRecursion Pharmaceuticals' early-October jump has already faded, and the shares still trade on short covering and hopes for the pipeline rather than on revenue. The REC-4881 polyposis data at the CGA-IGC Presidential Plenary on 2026-11-02 decide whether the lead drug can support the price.\n\nAdjusted daily closes show how fast the move reversed. The shares closed at $4.78 on 2026-10-05, then $4.27 on 2026-10-07 and $3.95 on 2026-10-08. The 2026-10-08 close sits 41.8% below the 52-week high of $6.79. StocksToTrade reported an early-October intraday high near $5.19 on 2026-10-08, with no offering, downgrade or company release behind the drop. The 14-day relative strength index (RSI) has cooled to 52.0 as of 2026-10-08, from 77.1 on 2026-10-05.\n\nThe narrative is maturing: the AI drug-discovery story has been public since the 2021 listing, and the 2026-10-05 spike gave back most of its gain within three sessions on no new company news. The business has not changed since the 2026-08-05 second-quarter release. Revenue was $7.7 million, against $19.2 million a year earlier. The case for the shares rests on one dataset in late October and early November, and before that readout the evidence shows no edge over the S&P 500.\n\n## Bull Case\n\n- **Lead data has a plenary slot.** The company's 2026-08-05 release places additional Phase 2 data for REC-4881, a MEK1/2 inhibitor for familial adenomatous polyposis, in Presidential Plenary I at the CGA-IGC meeting on 2026-11-02. The same release guides to an FDA update on a registrational path in the second half of 2026.\n- The company guides its runway \"into early 2028\" without new financing.\n- **Spending guidance came down.** On 2026-08-05 the company cut its 2026 cash operating expense guidance to under $375 million, from under $390 million.\n- **Tempus turned optional fees into committed cash.** On 2026-09-21 Tempus AI extended its data agreement through November 2029. Up to $84 million of discretionary fees became $42 million of committed payments over three years, per GenomeWeb and Investing.com.\n- **ARK is still buying.** Benzinga reported on 2026-10-06 that Cathie Wood's ARK funds bought Recursion shares while selling Twist Bioscience. Gotrade's stock page lists ARK's combined ARKK and ARKG holding at 40.46 million shares as of 2026-10-02.\n\n## Bear Case\n\n- **Revenue fell by more than half.** Second-quarter 2026 revenue was $7.7 million against $19.2 million a year earlier, and the net loss was $131.0 million, per the 2026-08-05 release. Cash fell from $753.9 million on 2025-12-31 to $556.8 million on 2026-06-30.\n- **The October spike did not hold.** The shares closed at $3.95 on 2026-10-08, 17% below the $4.78 close of 2026-10-05, per adjusted daily closes. StocksToTrade described a failed push above $5 with no company news attached.\n- **Insiders have only sold.** Quiver Quantitative counted 14 insider sales and no purchases over the six months to 2026-10-05. Two of those sales, by Chief Executive Officer Najat Khan, totaled about $163,281.\n- **Heavy shorting cuts both ways.** Short interest was 33.39% of float on 2026-10-02, per GuruFocus and Simply Wall St. Covering lifted the shares quickly into 2026-10-05 and the gain faded just as quickly.\n- **Analyst targets are mostly neutral.** Recent targets listed by TipRanks run from Morgan Stanley's $5.50 Equalweight (2026-05-14) and Bank of America's $6.00 Hold (2026-08-07) to Needham's $8.00 Buy (2026-08-05). None of those firms has changed its view since the second-quarter report.\n\n## Setup & Price Structure\n\nThe last close was $3.95 on 2026-10-08. The 52-week high is $6.79, 41.8% above that close. Over three months the shares are up 19.7%, per adjusted daily closes.\n\nStocksToTrade reported on 2026-10-08 that the shares had climbed roughly 60% from mid-September lows in the low $3s to an intraday high near $5.19 in early October. The same report noted trading support around $3.70 to $3.80 and resistance at $4.80 to $5.00. A daily close below $3.50 would give back most of that mid-September-to-October rally and put the shares back in the range they held before the Tempus deal.\n\nThe RSI of 52.0 on 2026-10-08 is neutral. The overbought reading of early October has fully cleared. Crowding comes from short interest above a third of the float, active call trading reported by Quiver Quantitative on 2026-10-05, and a binary data date about three weeks away.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-11-02** — Additional REC-4881 Phase 2 data in Presidential Plenary I at the CGA-IGC Annual Meeting in Denver (1:30–3:00 PM MST), per the company's 2026-08-05 release. This is the main dated test of the lead drug.\n- **~2026-11-04, est.** — Third-quarter 2026 financial report. It updates cash, spending against the under-$375 million guide and the timing of the REC-4881 FDA update. The company has not confirmed the date.\n- **~2026-12-31, est.** — FDA registrational-path update for REC-4881 and more REC-1245 Phase 1 data, both guided to the second half of 2026. This falls outside the 30-day window. The case depends on it because it shows what a registration trial would cost and how long it would take.\n\n## What Would Change Our Mind\n\nThe case breaks if the REC-4881 data on 2026-11-02 show a smaller polyp-burden reduction or worse tolerability than the earlier Phase 2 readout. That would remove the nearest path to a registrational program. A cut to the \"into early 2028\" runway guidance or an equity offering at the third-quarter report would also weaken it, because the pipeline would then be funded by dilution.\n\nOn price, a daily close below $3.50 would erase most of the rally that began in mid-September 2026 and show that short covering, not the Tempus deal, drove it.\n\nThe read would improve if the plenary data hold the earlier signal and the FDA confirms a registrational path that one trial can satisfy. A sustained recovery above the $4.80 to $5.00 range reported as resistance on 2026-10-08, together with falling short interest, would show real buying rather than covering.\n\n## Correlation Notes\n\nThe shares trade with small-cap biotech and with AI-themed growth names. They also track the precision-biotech group (Kodiak Sciences, Iovance, Moderna, Schrödinger, ImmunityBio), whose attention cooled again in the week to 2026-10-09 after a brief pickup earlier in October. A cooling group raises the bar for a single-name rally. Schrödinger is the closest peer on the computational drug-discovery story. ARK fund flows matter: ARK's ARKK and ARKG are large holders, and their buying or selling has moved the shares on days with no company news. Short-interest-driven moves also tie the shares loosely to other heavily shorted names on the same squeeze lists.",
  "first_seen": "2026-10-04",
  "last_analyzed": "2026-10-09T09:16:47+00:00",
  "last_synthesized": "2026-10-09",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}